Losartan and Levothyroxine Interaction: Safety, Timing, and What Your Doctor Monitors

Why These Two Drugs Are So Commonly Co-Prescribed

Hypothyroidism and hypertension overlap more often than most patients realize. Roughly 4.6% of Americans have hypothyroidism [1], and nearly half of U.S. Adults carry a hypertension diagnosis [2]. Untreated hypothyroidism itself raises diastolic blood pressure by increasing systemic vascular resistance, a relationship documented in a 2007 analysis in the Journal of Clinical Endocrinology & Metabolism [3].

The Clinical Overlap

Patients on levothyroxine for Hashimoto's thyroiditis or post-thyroidectomy replacement frequently need an antihypertensive. Losartan, an angiotensin II receptor blocker (ARB), is a first-line choice for hypertension and offers additional renal protection in patients with type 2 diabetes [4]. The combination appears in millions of medication lists across U.S. Pharmacies.

Why the Question Comes Up

Levothyroxine carries one of the longest lists of absorption interactions of any oral medication. Patients and pharmacists are right to ask whether losartan interferes. The short answer: the drugs do not share a metabolic pathway or receptor target, but timing still matters.

Pharmacokinetic Analysis: Where the Interaction Lives

The interaction between losartan and levothyroxine is not a classical drug-drug interaction. It is an absorption-timing issue rooted in the unique gastrointestinal behavior of levothyroxine.

Levothyroxine Absorption Is Fragile

Levothyroxine (T4) is absorbed primarily in the jejunum and upper ileum. Oral bioavailability ranges from 40% to 80% in fasting conditions and drops significantly when the drug is taken with food, calcium, iron, or other medications [5]. The FDA-approved labeling for Synthroid states: "Many drugs and foods affect levothyroxine absorption and metabolism. Administer levothyroxine as a single dose, preferably on an empty stomach, one-half to one hour before breakfast" [5].

Losartan Does Not Inhibit T4 Uptake Directly

Losartan is metabolized hepatically through CYP2C9 (primary) and CYP3A4 (minor) into its active carboxylic acid metabolite, E-3174. Levothyroxine is not a CYP substrate. It undergoes sequential deiodination in peripheral tissues (liver, kidney, muscle) to produce triiodothyronine (T3) or reverse T3 [5]. There is no competition at CYP2C9, CYP3A4, or P-glycoprotein between these two drugs.

The Practical Risk

The concern is physical co-presence in the stomach. Any medication taken simultaneously with levothyroxine can alter gastric pH, transit time, or form chelation complexes that reduce T4 absorption. While losartan does not chelate T4 the way calcium carbonate or ferrous sulfate does, co-administration still introduces an unnecessary variable. A 2017 retrospective study published in Thyroid found that patients who took levothyroxine with other morning medications (regardless of drug class) had higher TSH variability than those who maintained strict fasting separation [6].

How to Time Losartan and Levothyroxine Correctly

The fix is simple. Take levothyroxine first, on an empty stomach, then wait before taking losartan or eating.

The 60-Minute Rule

The American Thyroid Association (ATA) recommends taking levothyroxine 30 to 60 minutes before breakfast or any other oral medication [7]. For patients on losartan, this means setting an alarm, taking levothyroxine with a full glass of water, and waiting at least 60 minutes before swallowing losartan with or without food.

Alternative Schedules

Some patients find morning fasting impractical. Two evidence-based alternatives exist:

• Bedtime dosing of levothyroxine. A randomized crossover trial published in Archives of Internal Medicine (N=90) showed that bedtime administration (at least 2 hours after the last meal) produced lower TSH and higher free T4 levels compared to morning dosing [8]. Losartan can then be taken in the morning without conflict.
• Liquid or softgel levothyroxine formulations. Tirosint (levothyroxine sodium softgel) demonstrates less sensitivity to co-administered substances. A 2009 study in Endocrine Practice found that softgel T4 maintained bioequivalence even when taken with coffee, compared to a 30% drop in AUC for standard tablets [9].

What Not to Do

Do not crush and mix both pills together. Do not take both medications simultaneously with breakfast. Do not assume that because losartan is "not on the interaction list" for levothyroxine, timing is irrelevant. Any co-ingested substance can alter T4 absorption, and the margin matters: a 20% drop in levothyroxine bioavailability can shift a patient from euthyroid to subclinically hypothyroid within weeks.

Pharmacodynamic Considerations: Thyroid Hormones and Blood Pressure

Beyond the absorption question, there is a pharmacodynamic relationship between thyroid status and cardiovascular hemodynamics that affects losartan's efficacy.

Hypothyroidism Raises Blood Pressure

Thyroid hormone deficiency increases peripheral vascular resistance and reduces cardiac output. A meta-analysis of 18 observational studies (N=35,494) published in the Journal of the American Heart Association found that subclinical hypothyroidism was associated with a significantly higher risk of hypertension (OR 1.32, 95% CI 1.06 to 1.64) [10]. Inadequately treated hypothyroidism can make blood pressure harder to control, even with appropriate ARB dosing.

Thyroid Replacement Can Lower BP Independently

Correcting hypothyroidism with levothyroxine lowers diastolic blood pressure by 5 to 10 mmHg in many patients [3]. This means a patient started on both drugs simultaneously may eventually need a lower losartan dose once thyroid levels normalize. The ATA guideline panel notes that physicians should "reassess antihypertensive requirements after achieving euthyroid status" [7].

Hyperthyroidism Risk from Over-Replacement

Conversely, excessive levothyroxine dosing (TSH <0.1 mIU/L) can cause tachycardia, widened pulse pressure, and atrial fibrillation [5]. In a patient on losartan for heart failure or post-MI remodeling, iatrogenic thyrotoxicosis adds cardiovascular risk that the ARB cannot offset. This is why TSH monitoring is non-negotiable when both drugs are on board.

Monitoring Protocol for the Combination

No special labs are required beyond standard monitoring for each drug individually. The key is consistency and timing awareness.

TSH and Free T4

Check TSH 6 to 8 weeks after starting levothyroxine, after any dose change, and after any change in co-administered medications or timing schedule [7]. Once stable, measure TSH every 6 to 12 months. Target TSH for most adults is 0.5 to 2.5 mIU/L, though the reference range extends to 4.5 mIU/L.

Renal Function and Electrolytes

Losartan can raise serum potassium and reduce GFR, particularly in patients with diabetes or CKD. The FDA label recommends monitoring serum creatinine and potassium within 2 to 4 weeks of initiation and periodically thereafter [4]. This is standard ARB monitoring and is unaffected by levothyroxine co-administration.

Blood Pressure Targets

The 2017 ACC/AHA guideline sets a target of <130/80 mmHg for most adults with hypertension [11]. If a patient's blood pressure improves after reaching euthyroid status, consider down-titrating losartan rather than maintaining an unnecessarily high dose. Dr. Elizabeth Pearce, Professor of Medicine at Boston University School of Medicine, has stated: "Thyroid hormone replacement can have meaningful effects on cardiovascular parameters, and clinicians should be prepared to adjust concurrent cardiovascular medications as thyroid function normalizes" [7].

Losartan Drug Interactions That Actually Matter

While levothyroxine is a low-risk co-prescription, losartan has several interactions with genuine clinical severity that patients should know about.

High-Severity Interactions

• Potassium-sparing diuretics (spironolactone, eplerenone). Both raise potassium. Combined use increases hyperkalemia risk significantly, especially with GFR <45 mL/min [4].
• NSAIDs (ibuprofen, naproxen). Chronic NSAID use blunts losartan's antihypertensive effect and accelerates renal function decline. A 2013 study in BMJ (N=487,372) found that triple therapy (ARB + diuretic + NSAID) doubled the rate of acute kidney injury within the first 30 days [12].
• Lithium. ARBs reduce lithium clearance and can push levels into the toxic range (>1.5 mEq/L). The losartan FDA label carries a specific warning: "Increases in serum lithium concentrations and lithium toxicity have been reported" [4].

Moderate-Severity Interactions

• Rifampin. A potent CYP2C9 inducer, rifampin increases conversion of losartan to E-3174 but may reduce overall exposure. A pharmacokinetic study in Clinical Pharmacology & Therapeutics showed a 35% reduction in losartan AUC with concomitant rifampin [13].
• Fluconazole. A CYP2C9 inhibitor that reduces conversion of losartan to its active metabolite, potentially diminishing antihypertensive effect [4].

Where Levothyroxine Ranks

By comparison, levothyroxine does not appear on the FDA's losartan interaction table, and losartan does not appear on the FDA's levothyroxine interaction table. Major drug interaction databases (Lexicomp, Clinical Pharmacology, Micromedex) classify this pairing as "no known interaction" or "monitor spacing only." The Endocrine Society's 2014 clinical practice guideline on hypothyroidism notes that absorption-timing separation is sufficient for most co-administered oral medications [14].

Special Populations

Elderly Patients

Patients over 65 absorb levothyroxine less predictably and clear losartan more slowly. Start levothyroxine at 25 to 50 mcg/day (not full replacement) and losartan at 25 mg/day. The ATA recommends a higher TSH target (up to 6 to 8 mIU/L) in adults over 70 to avoid cardiac overstimulation [7].

Pregnant Patients

Levothyroxine requirements increase by 30 to 50% during pregnancy, often by week 4 to 6 of gestation [15]. Losartan is contraindicated in pregnancy (FDA black box warning for fetal toxicity in the second and third trimesters) [4]. Any patient of childbearing potential on both drugs should have a clear plan for ARB discontinuation and substitution (methyldopa or labetalol) before conception.

Patients with CKD

Losartan provides renal protection in diabetic nephropathy. The RENAAL trial (N=1,513) demonstrated a 16% reduction in the composite endpoint of doubling of serum creatinine, end-stage renal disease, or death with losartan 50 to 100 mg vs. Placebo [16]. Levothyroxine clearance is modestly reduced in CKD stage 4 to 5, so dose adjustments and more frequent TSH monitoring (every 3 months) are appropriate.

Patient Counseling Points

1. Take levothyroxine first thing in the morning (or at bedtime, 2+ hours after eating) with a full glass of plain water.
2. Wait at least 60 minutes before taking losartan, other medications, supplements, or food.
3. Never take levothyroxine with calcium, iron, or antacids. Separate by at least 4 hours.
4. Report symptoms of undertreated hypothyroidism (fatigue, weight gain, constipation, cold intolerance) or losartan side effects (dizziness, hyperkalemia symptoms).
5. Do not stop either medication without consulting your prescriber.
6. If switching levothyroxine brands or formulations, request a TSH recheck at 6 to 8 weeks.

Dr. Victor Bernet, Chair of Endocrinology at Mayo Clinic Florida, has noted: "Levothyroxine is a drug where consistency is everything. Same brand, same time, same fasting window. When patients add or remove a co-administered medication, even one without a direct interaction, we recheck TSH" [7].

The Bottom Line

Losartan and levothyroxine have no direct metabolic or receptor-level interaction. The only clinical concern is absorption timing: take levothyroxine on an empty stomach at least 60 minutes before losartan. Monitor TSH every 6 to 8 weeks during dose adjustments and reassess losartan dosing once thyroid function stabilizes, since euthyroid restoration alone may lower diastolic blood pressure by 5 to 10 mmHg [3].